DarioHealth Collaborates with Leading National Benefit Plan Administrator to Offer Cardiometabolic Solution including a GLP-1 Support Program to Employers
DarioHealth (Nasdaq: DRIO) has announced a strategic partnership with a leading national benefit administrator to provide its cardiometabolic solution, including a GLP-1 support program and AI-driven digital health suite to employers. The partnership, which began contributing to revenue in January 2025, addresses rising healthcare costs associated with metabolic conditions.
The collaboration targets the GLP-1 market, projected to reach $100 billion by 2030, and the cardiometabolic disease market, expected to exceed $1.2 trillion by 2033. Dario's comprehensive approach addresses the challenge of GLP-1 medication discontinuation through personalized coaching, AI-driven monitoring, and behavior change strategies.
This partnership marks Dario's first national benefit administrator collaboration, enabling faster employer onboarding and immediate impact on B2B2C recurring revenues for 2025. The agreement serves as a foundational entry into a priority growth segment and provides a reference model for expansion across other national administrators and payer channels.
DarioHealth (Nasdaq: DRIO) ha annunciato una partnership strategica con un importante amministratore nazionale di benefit per offrire la sua soluzione cardiometabolica, che include un programma di supporto GLP-1 e una suite di salute digitale basata su intelligenza artificiale, rivolta ai datori di lavoro. La collaborazione, che ha iniziato a generare ricavi a gennaio 2025, mira a contrastare l’aumento dei costi sanitari legati alle condizioni metaboliche.
La partnership si concentra sul mercato GLP-1, previsto raggiungere i 100 miliardi di dollari entro il 2030, e sul mercato delle malattie cardiometaboliche, che si stima supererà 1,2 trilioni di dollari entro il 2033. L’approccio completo di Dario affronta la sfida dell’interruzione della terapia con farmaci GLP-1 tramite coaching personalizzato, monitoraggio basato su AI e strategie di cambiamento comportamentale.
Questa collaborazione rappresenta la prima con un amministratore nazionale di benefit per Dario, permettendo un onboarding più rapido dei datori di lavoro e un impatto immediato sui ricavi ricorrenti B2B2C per il 2025. L’accordo costituisce un punto di partenza fondamentale in un segmento prioritario per la crescita e funge da modello di riferimento per l’espansione verso altri amministratori nazionali e canali di pagamento.
DarioHealth (Nasdaq: DRIO) ha anunciado una alianza estratégica con un administrador nacional líder de beneficios para ofrecer su solución cardiometabólica, que incluye un programa de apoyo GLP-1 y una suite de salud digital impulsada por IA dirigida a empleadores. La asociación, que comenzó a generar ingresos en enero de 2025, responde al aumento de los costos sanitarios relacionados con las condiciones metabólicas.
La colaboración se enfoca en el mercado GLP-1, proyectado para alcanzar los 100 mil millones de dólares para 2030, y en el mercado de enfermedades cardiometabólicas, que se espera supere 1,2 billones de dólares para 2033. El enfoque integral de Dario aborda el desafío de la interrupción del tratamiento con medicamentos GLP-1 mediante coaching personalizado, monitoreo impulsado por IA y estrategias de cambio de comportamiento.
Esta alianza representa la primera colaboración de Dario con un administrador nacional de beneficios, permitiendo una incorporación más rápida de empleadores y un impacto inmediato en los ingresos recurrentes B2B2C para 2025. El acuerdo sirve como una base para entrar en un segmento prioritario de crecimiento y ofrece un modelo de referencia para la expansión hacia otros administradores nacionales y canales de pago.
DarioHealth(나스닥: DRIO)는 주요 전국 복리후생 관리자와 전략적 파트너십을 발표하여 고용주에게 심혈관대사 솔루션을 제공합니다. 이 솔루션에는 GLP-1 지원 프로그램과 AI 기반 디지털 헬스 스위트가 포함되어 있습니다. 이 파트너십은 2025년 1월부터 매출에 기여하기 시작했으며, 대사 질환과 관련된 증가하는 의료 비용 문제를 해결합니다.
이번 협력은 2030년까지 1천억 달러에 이를 것으로 예상되는 GLP-1 시장과 2033년까지 1.2조 달러를 초과할 것으로 전망되는 심혈관대사 질환 시장을 겨냥합니다. Dario의 종합적인 접근법은 개인 맞춤형 코칭, AI 기반 모니터링, 행동 변화 전략을 통해 GLP-1 약물 중단 문제를 해결합니다.
이번 파트너십은 Dario의 첫 전국 복리후생 관리자 협력으로, 고용주 온보딩을 가속화하고 2025년 B2B2C 반복 수익에 즉각적인 영향을 미칩니다. 이 계약은 우선 성장 세그먼트에 진입하는 기반이자 다른 전국 관리자 및 지불 채널로 확장하기 위한 참조 모델 역할을 합니다.
DarioHealth (Nasdaq : DRIO) a annoncé un partenariat stratégique avec un administrateur national de prestations de premier plan pour fournir sa solution cardiométabolique, incluant un programme de soutien GLP-1 et une suite de santé digitale pilotée par IA aux employeurs. Ce partenariat, qui a commencé à générer des revenus en janvier 2025, répond à la hausse des coûts de santé liés aux troubles métaboliques.
La collaboration cible le marché du GLP-1, dont la valeur devrait atteindre 100 milliards de dollars d’ici 2030, ainsi que le marché des maladies cardiométaboliques, attendu à plus de 1,2 trillion de dollars d’ici 2033. L’approche globale de Dario répond au défi de l’arrêt des médicaments GLP-1 grâce à un coaching personnalisé, une surveillance pilotée par IA et des stratégies de changement de comportement.
Ce partenariat marque la première collaboration de Dario avec un administrateur national de prestations, permettant une intégration plus rapide des employeurs et un impact immédiat sur les revenus récurrents B2B2C en 2025. L’accord constitue une entrée fondamentale dans un segment de croissance prioritaire et offre un modèle de référence pour une expansion auprès d’autres administrateurs nationaux et canaux payeurs.
DarioHealth (Nasdaq: DRIO) hat eine strategische Partnerschaft mit einem führenden nationalen Leistungsadministrator angekündigt, um Arbeitgebern seine kardiometabolische Lösung anzubieten, die ein GLP-1-Unterstützungsprogramm und eine KI-gesteuerte digitale Gesundheitsplattform umfasst. Die Partnerschaft, die ab Januar 2025 Umsätze generiert, zielt darauf ab, steigende Gesundheitskosten im Zusammenhang mit Stoffwechselerkrankungen zu bewältigen.
Die Zusammenarbeit fokussiert den GLP-1-Markt, der bis 2030 voraussichtlich 100 Milliarden US-Dollar erreichen wird, sowie den Markt für kardiometabolische Erkrankungen, der bis 2033 über 1,2 Billionen US-Dollar liegen soll. Darios ganzheitlicher Ansatz begegnet der Herausforderung der Abbruchraten bei GLP-1-Medikamenten durch personalisiertes Coaching, KI-gestützte Überwachung und Verhaltensänderungsstrategien.
Diese Partnerschaft markiert Darios erste Zusammenarbeit mit einem nationalen Leistungsadministrator und ermöglicht eine schnellere Einbindung von Arbeitgebern sowie sofortige Auswirkungen auf wiederkehrende B2B2C-Umsätze im Jahr 2025. Die Vereinbarung dient als grundlegender Einstieg in ein prioritäres Wachstumssegment und bietet ein Referenzmodell für die Expansion zu weiteren nationalen Administratoren und Kostenträgerkanälen.
- None.
- None.
Strategic partnership expands Dario's employer footprint and has already started contributing to recurring revenues in Q1 of 2025
The benefit administrator selected Dario's integrated platform to address rising healthcare costs associated with metabolic conditions including diabetes, pre-diabetes, hypertension, and weight management. The partnership specifically targets the growing demand for effective GLP-1 medication support as employers seek solutions that maximize the clinical and economic benefits of these breakthrough therapies while ensuring sustainable outcomes for members.
This collaboration expands Dario's footprint in multiple fast-growing healthcare segments, including the GLP-1 market projected to grow to
"We are thrilled to partner with one of the fastest growing benefits administrators in the country to support their goals of delivering market-leading health benefits that help reduce costs associated with healthcare," said Steven Nelson, Chief Commercial Officer at Dario. "This strategic partnership unlocks new distribution channels that align with payer-driven models such as Third Party Administrators (TPAs) and benefits platforms, as well as expanding in the employer market. Due to the shorter sales cycle, we were able to begin onboarding employers quickly after the January launch, with the ability to add employers off-cycle as well, maximizing the availability of Dario's solutions to the employer population and creating an immediate impact on our Business-to-Business-to-Consumer (B2B2C) recurring revenues for 2025. This partnership highlights our solution to the growing challenge clients face as healthcare costs continue to increase, particularly for chronic conditions and GLP-1 medications. We view this partnership as a foundational entry into a priority growth segment."
We believe that this agreement further validates Dario's position as a leading provider of integrated digital health solutions addressing the complex challenges of chronic condition management, particularly as employers and health plans seek effective strategies to manage the rising costs associated with GLP-1 medications while ensuring optimal health outcomes. We believe it also provides a proven reference model we can replicate across other national administrators and payer channels, reinforcing our B2B2C strategy.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses that the GLP-1 market is projected to grow to
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
1 I. GLP-1 Market: https://www.goldmansachs.com/insights/articles/anti-obesity-drug-market; II. Cardiometabolic Disease Market: https://straitsresearch.com/report/cardiometabolic-disease-market
Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:SOURCE DarioHealth Corp.
FAQ
What is the projected market size for GLP-1 medications by 2030 according to DarioHealth's announcement?
How does DarioHealth (DRIO) address GLP-1 medication discontinuation rates?
When did DarioHealth's new benefit administrator partnership begin generating revenue?
What is the projected size of the cardiometabolic disease market by 2033 mentioned in DRIO's announcement?
What percentage of patients discontinue GLP-1 medications within one year without proper support?
